Duration and outcomes of LEN/PEM combination therapy
| Patient | Duration of LEN/PEM therapy | PFS | Status at time of last follow-up* | Patient on treatment at time of data cut-off |
| 1 | 22 months | 19 months | AWD | Yes |
| 2 | 10 months | 6 months | AWD | Yes |
| 3 | 2 months | 2 months | AWD | No |
| 4 | 10 months | 5 months | AWD | Yes |
| 5 | 8 months | 8 months | AWD | Yes |
| 6 | 3 months | 2 months | DOD | No |
| 7 | 3 months | 3 months | DOD | No |
| 8 | 9 months | 9 months | AWD | Yes |
*Date of data cut-off: December 31, 2019.
AWD, alive with disease; DOD, died of disease; LEN, lenvatinib; PEM, pembrolizumab; PFS, progression-free survival.